Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE)
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into Securities Purchase Agreements (“SPAs”) for the private placement of 700,001 shares of common stock at a price of $3.00 per share (the “Shares”), for total proceeds of $2,100,000. The private placement investors include members of Management and the Board of Directors of the Company and Keystone Capital Partners, LLC (collectively, “Investors”). No warrants or brokers fees were issued in this financing transaction.
Published: Mar 08, 2021
Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial
(“Spectral” or the “Company”) (TSX: EDT), today announced the appointment of Chris Seto to Chief Executive Officer (“CEO”), effective April 1, 2021. In his new role, Mr. Seto will continue to serve as the Company’s Chief Financial Officer (“CFO”). Dr. Paul Walker, current CEO, will remain committed to the Company as a member of the Board of Directors, where he will be responsible for a seamless transition of leadership, and focus his efforts on the Tigris Trial supporting Dr. John Kellum, Spectral’s recently announced Chief Medical Officer.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and .
Adial Pharmaceuticals, IncFebruary 26, 2021 GMT
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.
Information for shareholders interested in attending will be available at the Company’s Investors section of the website: https://ir.adialpharma.com/
ADVERTISEMENT
About Adial Pharmaceuticals, Inc.
25.02.2021 - CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% .
Published: Feb 25, 2021
CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) ADial Pharmaceuticals
, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial. ONWARD is investigating the efficacy and safety of Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.
“We are pleased to have achieved this important enrollment milestone in our ONWARD pivotal Phase 3 clinical trial,” stated Schuyler Vinzant, Adial’s Vice President of Development. “We have a high degree of confidence that ONWARD will be fully enrolled this summer.”